Abstract
Aims: Diabetes Mellitus predisposes patients to invasive fungal infections. There has been a recent surge of Mucormycosis with COVID 19 infection particularly in patients with diabetes. This study aims to study the clinical spectrum of CAM (COVID -associated Mucormycosis) with diabetes and subsequent outcomes.
Material and methods: This was a descriptive study conducted at a single COVID Care Centre in India in patients with COVID Associated Mucormycosis from April 12, 2021 to May 31, 2021.
Results: Among 953 hospitalized patients with COVID 19 infection, 32 patients had CAM with an incidence of 3.36%. In patients with CAM, 87.5% had Diabetes Mellitus as the most common co-morbidity. The majority of the patients had poor glycemic control with a mean HbA1c of 9.06%. Out of the total study population, 93% had prior exposure to high dose corticosteroids. During the study period, 12.5% patients of CAM did not survive.
Conclusion: Mucormycosis is an angioinvasive fungal infection with high mortality. The disease has surged in COVID 19 pandemic due to uncontrolled diabetes and improper corticosteroid use.
Keywords: COVID-19; Diabetes; Mucormycosis.
【저자키워드】 COVID-19, diabetes, Mucormycosis, 【초록키워드】 Corticosteroid, High dose, Corticosteroids, pandemic, India, Infection, COVID, COVID 19, outcomes, Patient, co-morbidity, incidence, fungal infections, disease, glycemic control, Fungal infection, study population, study period, high mortality, material, invasive, the patient, subsequent, conducted, majority, hospitalized patient, diabete, patients with diabetes, 【제목키워드】 India, outcome, COVID 19, clinical, Care,